Particulate Risk Prompts Gilead Sciences to Recall Vistide Injections

Posted on February 19, 2013

Vistide (cidofovir injection) from lot number B120217A is being recalled by Gilead Sciences.  Certain vials were shown to contain particulates, and thus those versions of the injection with an expiration date of May 2015 are being recalled.  No one has reported sustaining any type of adversity in conjunction with this item, but the company takes pains to note that the presence of particulates in an injectable substance could cause severe health woes.  The drug, which is used to treat cytomegalovirus retinitis in persons who suffer from AIDS, should be inspected, and those versions shown to be from the aforementioned lot ought not to be used.  Patients who think they may have received the item should speak with their doctors.

Click here to learn more about the recall.

How Can We Help You?

If you have a legal matter you would like to discuss with an attorney from our firm, please call us at (310) 477-1700 or complete and submit the e-mail form below, and we will get back to you.

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.
*Required Fields